文献速递糖尿病肥胖与代谢综合征

长期给予肉豆蔻酸改善先天性2型糖尿病Nagoya-Shibata-Yasuda小鼠模型的高血糖

Chronic administration of myristic acid improves hyperglycaemia in the Nagoya-Shibata-Yasuda mouse model of congenital type 2 diabetes.
PubMed 文献 · Diabetologia · 2017-07-13

本研究在先天性2型糖尿病NSY小鼠模型中,从4周龄起隔日口服给予肉豆蔻酸300 mg/kg、棕榈酸300 mg/kg或溶剂,至24-30周龄时肉豆蔻酸组较溶剂组和棕榈酸组改善糖耐量并降低胰岛素反应性血糖,还减轻体重增加并升高骨骼肌DGKδ水平。作者认为肉豆蔻酸是预防和治疗2型糖尿病及其相关疾病的潜在候选物。

要点

  • NSY小鼠隔日口服肉豆蔻酸300 mg/kg可改善糖耐量并降低胰岛素反应性血糖。
  • 肉豆蔻酸减轻NSY小鼠体重增加,并升高骨骼肌DGKδ水平约1.6倍。
  • 作者认为肉豆蔻酸是预防和治疗2型糖尿病及其相关疾病的潜在候选物。

核心结论

  • 作者认为长期口服肉豆蔻酸通过降低胰岛素反应性血糖和减轻体重改善高血糖,并认为该脂肪酸可解释高脂乳制品的糖尿病保护特性。
  • 作者认为肉豆蔻酸是预防和治疗2型糖尿病及其相关疾病的潜在候选物。

研究设计与样本

  • 雄性NSY小鼠从4周龄起隔日口服给予溶剂(n=9)、肉豆蔻酸300 mg/kg(n=14)或棕榈酸300 mg/kg(n=9)。
  • 于第18、24和30周进行葡萄糖耐量试验,于第20和26周进行胰岛素耐量试验。
  • 通过蛋白质印迹法测定32-36周龄NSY小鼠骨骼肌中的DGKδ水平。

主要发现

  • 在24-30周龄时,肉豆蔻酸组较溶剂组和棕榈酸组葡萄糖耐量试验中血糖水平降低24-28%。
  • 在24-30周龄时,肉豆蔻酸组较溶剂组和棕榈酸组胰岛素反应性血糖降低约20%。
  • 肉豆蔻酸减轻NSY小鼠的体重增加。
  • 肉豆蔻酸使NSY小鼠骨骼肌DGKδ水平升高约1.6倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Previously, we demonstrated that myristic acid (14:0) increases levels of diacylglycerol kinase (DGK) δ, a key enzyme involved in type 2 diabetes exacerbation, and enhances glucose uptake in C2C12 myotube cells. Moreover, results from a population-based cohort study suggest that consumption of high-fat dairy products, which contain high amounts of myristic acid, is associated with a lower risk of developing type 2 diabetes. Taken together, we hypothesised that intake of myristic acid reduces type 2 diabetes risk in vivo. The aim of this study was to examine the glucose-lowering effect of myristic acid in Nagoya-Shibata-Yasuda (NSY) mice, a spontaneous model for studying obesity-related type 2 diabetes. METHODS: Male NSY mice were orally administered vehicle (n = 9), 300 mg/kg of myristic acid (n = 14) or 300 mg/kg of palmitic acid (16:0) (n = 9) every other day from 4 weeks of age. Glucose and insulin tolerance tests were performed at weeks 18, 24 and 30, and weeks 20 and 26, respectively. DGKδ levels were measured in skeletal muscle from 32-36-week-old NSY mice via western blot. RESULTS: Chronic oral administration of myristic acid ameliorated glucose tolerance (24-28% decrease in blood glucose levels during glucose tolerance tests) and reduced insulin-responsive blood glucose levels (~20% decrease) in male NSY mice compared with vehicle and palmitic acid groups at 24-30 weeks of age (the age at which the severity of type 2 diabetes is exacerbated in NSY mice). Myristic acid also attenuated the increase in body weight seen in NSY mice. Furthermore, the fatty acid increased DGKδ levels (~1.6-fold) in skeletal muscle of NSY mice. CONCLUSIONS/INTERPRETATION: These results suggest that the chronic oral administration of myristic acid improves hyperglycaemia by decreasing insulin-responsive glucose levels and reducing body weight, and that the fatty acid accounts for the diabetes protective properties of high-fat dairy products. Myristic acid is a potential candidate for the prevention and treatment of type 2 diabetes mellitus and its related diseases.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Takato T, Iwata K, Murakami C, et al. Chronic administration of myristic acid improves hyperglycaemia in the Nagoya-Shibata-Yasuda mouse model of congenital type 2 diabetes. Diabetologia. 2017. PMID: 28707095. doi:10.1007/s00125-017-4366-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。